Jessica L. Mega, MD, MPH, is the Chief Medical and Scientific Officer at Verily Life Sciences. As CMO, Dr. Mega’s focus is on translating technological innovations and scientific insights into partnerships and programs that improve patient outcomes. She oversees all of Verily’s clinical and science efforts, including the Baseline Study.
As a faculty member at Harvard Medical School, a senior investigator with the TIMI Study Group, and a cardiologist at Brigham and Women’s Hospital, she led large, international, randomized trials evaluating novel cardiovascular therapies. She also directed the TIMI Study Group’s Genetics Program. Her findings have been published in the New England Journal of Medicine, Lancet, JAMA, and elsewhere. Dr. Mega sits on the advisory group for the California Governor on Precision Medicine and Danaher’s Board of Directors.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital, and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC).